Cargando…
A call to caution when hydroxychloroquine is given to elderly patients with COVID-19
INTRODUCTION: Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-19) was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk of hydroxychloroquine interactions with co-morbidities and co-medications contributing to detrimental, inclu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035801/ https://www.ncbi.nlm.nih.gov/pubmed/33848675 http://dx.doi.org/10.1016/j.ijid.2021.04.009 |
_version_ | 1783676776186118144 |
---|---|
author | Gabor, Julian J. Kreidenweiss, Andrea Weber, Stefan Salama, Moaaz Sulyok, Mihaly Sulyok, Zita Koehne, Erik Esen, Meral Kreuels, Benno Shamsrizi, Parichehr Biecker, Erwin Mordmüller, Benjamin Berg, Christoph P. Fusco, Stefano Köhler, Carsten Kubicka, Stefan Leitlein, Jens Addo, Marylyn Ramharter, Michael Schwab, Matthias Bissinger, Alfred Lennart Velavan, Thirumalaisamy P. Krishna, Sanjeev Kremsner, Peter G. |
author_facet | Gabor, Julian J. Kreidenweiss, Andrea Weber, Stefan Salama, Moaaz Sulyok, Mihaly Sulyok, Zita Koehne, Erik Esen, Meral Kreuels, Benno Shamsrizi, Parichehr Biecker, Erwin Mordmüller, Benjamin Berg, Christoph P. Fusco, Stefano Köhler, Carsten Kubicka, Stefan Leitlein, Jens Addo, Marylyn Ramharter, Michael Schwab, Matthias Bissinger, Alfred Lennart Velavan, Thirumalaisamy P. Krishna, Sanjeev Kremsner, Peter G. |
author_sort | Gabor, Julian J. |
collection | PubMed |
description | INTRODUCTION: Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-19) was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk of hydroxychloroquine interactions with co-morbidities and co-medications contributing to detrimental, including fatal, adverse treatment effects. METHODS: A retrospective survey was undertaken of health conditions and co-medications of patients with COVID-19 who were pre-screened for enrolment in a randomized, double-blind, placebo-controlled hydroxychloroquine multi-centre trial. RESULTS: The survey involved 305 patients [median age 71 (interquartile range 59–81) years]. The majority of patients (n = 279, 92%) considered for inclusion in the clinical trial were not eligible, mainly due to safety concerns caused by health conditions or co-medications. The most common were QT-prolonging drugs (n = 188, 62%) and haematologic/haemato-oncologic diseases (n = 39, 13%) which prohibited the administration of hydroxychloroquine. In addition, 165 (54%) patients had health conditions and 167 (55%) patients were on co-medications that did not prohibit the use of hydroxychloroquine but had a risk of adverse interactions with hydroxychloroquine. The most common were diabetes (n = 86, 28%), renal insufficiency (n = 69, 23%) and heart failure (n = 58, 19%). CONCLUSION: The majority of hospitalized patients with COVID-19 had health conditions or took co-medications precluding safe treatment with hydroxychloroquine. Therefore, hydroxychloroquine should be administered with extreme caution in elderly patients with COVID-19, and only in clinical trials. |
format | Online Article Text |
id | pubmed-8035801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80358012021-04-12 A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 Gabor, Julian J. Kreidenweiss, Andrea Weber, Stefan Salama, Moaaz Sulyok, Mihaly Sulyok, Zita Koehne, Erik Esen, Meral Kreuels, Benno Shamsrizi, Parichehr Biecker, Erwin Mordmüller, Benjamin Berg, Christoph P. Fusco, Stefano Köhler, Carsten Kubicka, Stefan Leitlein, Jens Addo, Marylyn Ramharter, Michael Schwab, Matthias Bissinger, Alfred Lennart Velavan, Thirumalaisamy P. Krishna, Sanjeev Kremsner, Peter G. Int J Infect Dis Article INTRODUCTION: Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-19) was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk of hydroxychloroquine interactions with co-morbidities and co-medications contributing to detrimental, including fatal, adverse treatment effects. METHODS: A retrospective survey was undertaken of health conditions and co-medications of patients with COVID-19 who were pre-screened for enrolment in a randomized, double-blind, placebo-controlled hydroxychloroquine multi-centre trial. RESULTS: The survey involved 305 patients [median age 71 (interquartile range 59–81) years]. The majority of patients (n = 279, 92%) considered for inclusion in the clinical trial were not eligible, mainly due to safety concerns caused by health conditions or co-medications. The most common were QT-prolonging drugs (n = 188, 62%) and haematologic/haemato-oncologic diseases (n = 39, 13%) which prohibited the administration of hydroxychloroquine. In addition, 165 (54%) patients had health conditions and 167 (55%) patients were on co-medications that did not prohibit the use of hydroxychloroquine but had a risk of adverse interactions with hydroxychloroquine. The most common were diabetes (n = 86, 28%), renal insufficiency (n = 69, 23%) and heart failure (n = 58, 19%). CONCLUSION: The majority of hospitalized patients with COVID-19 had health conditions or took co-medications precluding safe treatment with hydroxychloroquine. Therefore, hydroxychloroquine should be administered with extreme caution in elderly patients with COVID-19, and only in clinical trials. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-05 2021-04-10 /pmc/articles/PMC8035801/ /pubmed/33848675 http://dx.doi.org/10.1016/j.ijid.2021.04.009 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Gabor, Julian J. Kreidenweiss, Andrea Weber, Stefan Salama, Moaaz Sulyok, Mihaly Sulyok, Zita Koehne, Erik Esen, Meral Kreuels, Benno Shamsrizi, Parichehr Biecker, Erwin Mordmüller, Benjamin Berg, Christoph P. Fusco, Stefano Köhler, Carsten Kubicka, Stefan Leitlein, Jens Addo, Marylyn Ramharter, Michael Schwab, Matthias Bissinger, Alfred Lennart Velavan, Thirumalaisamy P. Krishna, Sanjeev Kremsner, Peter G. A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 |
title | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 |
title_full | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 |
title_fullStr | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 |
title_full_unstemmed | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 |
title_short | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 |
title_sort | call to caution when hydroxychloroquine is given to elderly patients with covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035801/ https://www.ncbi.nlm.nih.gov/pubmed/33848675 http://dx.doi.org/10.1016/j.ijid.2021.04.009 |
work_keys_str_mv | AT gaborjulianj acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kreidenweissandrea acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT weberstefan acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT salamamoaaz acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT sulyokmihaly acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT sulyokzita acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT koehneerik acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT esenmeral acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kreuelsbenno acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT shamsriziparichehr acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT bieckererwin acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT mordmullerbenjamin acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT bergchristophp acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT fuscostefano acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kohlercarsten acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kubickastefan acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT leitleinjens acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT addomarylyn acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT ramhartermichael acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT schwabmatthias acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT bissingeralfredlennart acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT velavanthirumalaisamyp acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT krishnasanjeev acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kremsnerpeterg acalltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT gaborjulianj calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kreidenweissandrea calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT weberstefan calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT salamamoaaz calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT sulyokmihaly calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT sulyokzita calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT koehneerik calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT esenmeral calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kreuelsbenno calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT shamsriziparichehr calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT bieckererwin calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT mordmullerbenjamin calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT bergchristophp calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT fuscostefano calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kohlercarsten calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kubickastefan calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT leitleinjens calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT addomarylyn calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT ramhartermichael calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT schwabmatthias calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT bissingeralfredlennart calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT velavanthirumalaisamyp calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT krishnasanjeev calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 AT kremsnerpeterg calltocautionwhenhydroxychloroquineisgiventoelderlypatientswithcovid19 |